PMH23 IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON HOSPITALIZATION AND MEDICATION USE IN PATIENTS WITH SCHIZOPHRENIA  by Beauclair, L et al.
A202 Abstracts
harming others and/or themselves. Therefore the importance of
preventing deterioration in a patient’s condition as measured by
PANSS is not only beneﬁcial to the patient but also to society.
Given the difﬁculties in this patient population about maintain-
ing treatment compliance, it may be worthwhile to allocate funds
aimed at reducing symptoms directly or indirectly by improving
compliance.
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OBJECTIVES: Clinical trials have demonstrated the efﬁcacy of
atypical antipsychotic agents in reducing symptoms of schizo-
phrenia. However, the likelihood of sustaining control of schiz-
ophrenic symptoms may depend on treatment persistence. In this
study, we compared treatment persistence between patients who
were initiated on risperidone or olanzapine, the two most widely
prescribed atypical antipsychotic agents. METHODS: We iden-
tiﬁed patients with schizophrenia by ICD-9-CM codes (>1 inpa-
tient or >2 outpatient ICD-9-CM codes >7 days apart) between
July 1, 1998 and June 30, 1999. We further selected those who
were prescribed the target drug during April 1, 1999 through
March 31, 2000 provided that they were not on any antipsy-
chotic agents during the prior six months. Using event history
analysis, we compared treatment persistence in terms of hazard
ratio between olanzapine and risperidone initiators, adjusting for
patient sociodemographic and clinical characteristics. RESULTS:
Following the initiation of the target drug, more patients
switched from risperidone to olanzapine than visa versa. Olan-
zapine initiators had decreased hazards of discontinuation by
14% (unadjusted; p < 0.001) and 12% (adjusted; p = 0.002),
respectively, than risperidone initiators. CONCLUSIONS: Com-
pared with risperidone, olanzapine seems to be better tolerated
by patients as indicated by better treatment persistence. The ini-
tiation of olanzapine may thus increase the likelihood of sus-
taining control of symptoms of schizophrenia. Future research
needs to provide a more comprehensive assessment of treatment
persistence by considering other factors, such as formulary deci-
sion, and other antipsychotic agents in the study and developing
models to assess treatment persistence and switching as two
interdependent competing risks.
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OBJECTIVE: To compare time to ﬁrst psychiatric-related hos-
pitalization and time to ﬁrst medication switch in schizophrenia
patients receiving risperidone long-acting injectable (RLAI) or a
new oral atypical antipsychotic. METHODS: Study sites partic-
ipating in RLAI clinical trials in Canada carried out a retro-
spective chart review of hospitalization and medication use in
schizophrenia patients initiated on RLAI between June 1, 1999
and November 30, 2000. Identical parameters were assessed in
similar patients initiated on a new oral atypical antipsychotic
(control patients) over the same period. RESULTS: Sixty-three
RLAI and 74 control charts were reviewed. Control patients
were signiﬁcantly younger than those in the RLAI group (39.1
years versus 45.3, p = 0.0073) and received risperidone (48.6%),
olanzapine (41.9%) and quetiapine (6.8%) as the oral atypical
antipsychotic. Over the assessment periods, 56.8% of control
patients were hospitalized versus 4.8% of RLAI patients (p <
0.0001). For those patients hospitalized, time to ﬁrst hospital-
ization was marginally but not signiﬁcantly lower for RLAI
patients at 13.8 months compared to 19.3 months for the control
patients, respectively (p = 0.6365). However, control patients
had a signiﬁcantly increased risk of hospitalization, as indicated
by Kaplan Meier survival analysis (p < 0.0001 by log-rank test).
There was no signiﬁcant difference in the number of patients
switching medication (47.6% and 59.5% for RLAI and controls
respectively, p = 0.1742) or in time to ﬁrst medication switch
(39.71 and 34.52 months, log-rank p = 0.2076). However, time
to relapse, deﬁned as a hospitalization or a medication switch,
was signiﬁcantly different (p = 0.0004 by log-rank test) with
50% of controls reaching this endpoint at 18 months versus 60
months for RLAI patients. CONCLUSIONS: This study pro-
vides evidence that RLAI is superior to oral atypicals in reduc-
ing hospitalizations. Furthermore, by virtue of its bi-weekly
administration, RLAI offers atypical therapy without the serious
compliance issues associated with an oral medication, providing
clinical and potential economic advantages.
PMH23
IMPACT OF RISPERIDONE LONG-ACTING INJECTABLE ON
HOSPITALIZATION AND MEDICATION USE IN PATIENTS
WITH SCHIZOPHRENIA
Beauclair L1, Lam A2, McCormick J3, Luong D2, Camacho F4
1McGill University, Montreal, QC, Canada; 2Janssen-Ortho Inc,
Toronto, ON, Canada; 3McKesson Phase 4 Solutions,Toronto, ON,
Canada; 4Damos Inc,Toronto, ON, Canada
OBJECTIVE: To compare psychiatric-related hospitalization
and medication use in patients with schizophrenia, before and
after initiation of risperidone long-acting injectable (RLAI)
therapy. METHODS: Schizophrenia patients who participated in
RLAI clinical trials in Canada were identiﬁed and their charts
were retrospectively reviewed to assess hospitalization and med-
ication use over identical periods before and after the initiation
of RLAI therapy. RESULTS: Sixty-three charts were reviewed.
The mean RLAI treatment period was 40.3 months with 52.4%
of patients still receiving therapy at the time of the chart audit.
The pre- and post-RLAI assessment periods were identical at
39.4 and 40.3 months, respectively (p = 0.8293). There were sta-
tistically signiﬁcant differences in hospitalization before and after
the initiation of RLAI therapy. After initiation of RLAI therapy
fewer patients were hospitalized (52.4% prior to RLAI versus
4.8% during RLAI treatment, Relative Risk = 10.9, p < 0.0001),
fewer patients had more than one hospitalization (24% versus
0%, p < 0.0001), the total duration of hospitalization days
decreased by 99% (1558 versus 23, p < 0.0001), the number of
hospitalizations per patient decreased by 89% (0.9 versus 0.1, 
p < 0.0001) and duration of hospitalization decreased by 98%
(24.7 days per patient versus 0.4, p < 0.0001). Furthermore, anti-
cholinergic and anxiolytic use decreased from 81% of patients
to 64% (p = 0.0459) and 57% to 35% (0.0198), respectively,
with RLAI while sedative use was not signiﬁcantly different
(22% and 16% of patients used sedatives pre- and post-RLAI,
respectively, p = 0.4967). CONCLUSIONS: RLAI had a signiﬁ-
cant impact on hospitalization of schizophrenia patients, offer-
ing a clear clinical beneﬁt compared to traditional antipsychotic
therapy. In addition, the signiﬁcant decrease in hospitalization
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with RLAI offers the potential for substantial cost savings in the
care of these patients.
PMH24
GEO OBSERVATIONAL STUDY: 24 MONTHS
CHARACTERISTICS OF SOCIOECONOMIC AND CLINICAL
STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH
OLANZAPINE AND HALOPERIDOL IN GERMANY
Eichmann F1, Reitberger U1, Clouth J2, Czekalla J2
1Kendle GmbH & Co GMI KG, Munchen, Germany; 2Lilly Deutschland
GmbH, Bad Homburg, Germany
OBJECTIVES: To describe real life disease characteristics, clini-
cal status and socioeconomics for schizophrenia in- and outpa-
tients treated with olanzapine or haloperidol over 24 months.
METHODS: GEO is a two-year prospective naturalistic study in
Germany. Quarterly observations were made for 308 patients
under olanzapine treatment and 188 patients under haloperidol
treatment. RESULTS: Compared to haloperidol patients, more
patients included into the study under olanzapine lived at home
without care (59% vs. 39%), were employed (35% vs. 17%),
and fewer were in early retirement (30% vs. 51%). During the
observational period, olanzapine and haloperidol treatment was
stable (olanzapine: 94% retention vs. haloperidol: 92%; dosage
changes occurred in 64% vs. 47%, respectively). Concomitant
medication related to schizophrenia was prescribed less fre-
quently for olanzapine patients (52% vs. 68%). Mean disease
severity, negative and cognitive symptoms as assessed by CGI
(scales from no symptoms (one) to very severe (seven)) ranged
between three and four. Positive and depressive symptom values
were lower (mean value between two and three). During the
course of the study disease severity improved for all symptoms
with slightly more improvement in olanzapine patients (mean
change in disease severity: olanzapine 0.95; haloperidol 0.76).
Throughout the 24-month period, olanzapine patients had lower
average EPS, parkinsonism, retardation, dyskinesia and akathisia
symptom scores (none (1) to severe (6)) than haloperidol patients
(mean EPS: olanzapine 1.3; haloperidol 2.0). Weight gain,
depression and other symptoms were reported more frequently
for olanzapine (<28% vs. <11%). Nevertheless, olanzapine
patients showed a lower mean Body Mass Index (BMI) than
haloperidol patients throughout the 24-month study period.
CONCLUSIONS: Schizophrenia patients under olanzapine
treatment showed a higher degree of integration into social and
occupational environment. For olanzapine patients, all schizo-
phrenia symptoms improved over time. Throughout the study,
olanzapine patients exhibited less EPS and had a lower BMI.
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OBJECTIVE: To compare effectiveness and tolerability out-
comes of patients with schizophrenia treated with risperidone
long-acting injection and patients treated with conventional
depot antipsychotics. METHODS: Patients initiated on risperi-
done long-acting injection during a four-month index period
were compared to patients initiated on a conventional depot
antipsychotic during the same time period. Patient demograph-
ics including age, gender, diagnosis, number of previous psychi-
atric admissions and in-patient program were evaluated. The
effectiveness outcomes of antipsychotic polypharmacy, discharge
and readmission rates were compared. Neurological tolerability
was assessed as measured by the prescribing of regularly sched-
uled anticholinergic rescue medications. RESULTS: Forty
patients initiated on risperidone long-acting injection were com-
pared to 49 patients initiated on a conventional depot antipsy-
chotic. The two patient groups were demographically very
similar. The risperidone long-acting injection group was 75%
male with an average age of 41-years and 6.0 previous psychi-
atric admissions. The conventional depot group was 67% male
with an average age of 47.5 years and 5.9 previous psychiatric
admissions. Antipsychotic polypharmacy was reduced from 63%
to 31% in the risperidone long-acting injection group but
increased from 29% to 73% in the conventional depot group.
The use of anticholinergic rescue medications decreased from
47% to 12% in the risperidone long-acting injection group but
increased from 31% to 73% in the conventional depot group.
After 12-months of observation, 83% of the risperidone long-
acting injection patients had been discharged and none had been
readmitted, whereas 58% of the conventional depot group had
been discharged and, of those, 26% had already been readmit-
ted. CONCLUSION: In this difﬁcult-to-treat population of
patients, risperidone long-acting injection conferred signiﬁcant
advantages over conventional depot antipsychotics in terms of
effectiveness and tolerability. As well, the substantial differences
in discharge and readmission rates infer considerable phar-
macoeconomic advantages in favor of risperidone long-acting
injection.
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OBJECTIVES: This study estimates the annual prevalence of
schizophrenia in the U.S. based on administrative claims data
analyses and a comprehensive literature review. METHODS:
The 2002 annual prevalence rate of schizophrenia in the U.S.
was estimated separately for privately insured, government
insured (Medicare, Medicaid), and uninsured populations. The
2002 annual prevalence for privately insured individuals was cal-
culated based on a de-identiﬁed administrative claims database
of approximately 3.0 million privately insured beneﬁciaries cov-
ering the period from 1999 to 2003. The 2002 prevalence of
Medicaid enrollees was calculated from Medi-Cal claims cover-
ing the period from 2000–2002. The 2002 schizophrenia preva-
lence in Medicare population was calculated as a weighted
average of the prevalence rates of Medicaid/Medicare dual eligi-
bles and private insurance program enrollees over 65. Published
statistics were used to estimate the prevalence of schizophrenia
in the uninsured population and to weight prevalence rates in
different populations to estimate the 2002 annual schizophrenia
prevalence in the general U.S. population. RESULTS: The annual
prevalence rate of schizophrenia in the U.S. in 2002 was esti-
mated at 0.5%. The Medicaid population was identiﬁed as
having the highest schizophrenia prevalence rate in the U.S.
(1.7% for non Medicare dual eligible enrollees), whereas annual
schizophrenia prevalence rates in Medicare and privately insured
population were 0.7% and 0.1%, respectively. The disease was
also more prevalent in the uninsured population (1.1%). Preva-
lence rates for women were highest in an older age group (56–65
years), whereas men’s prevalence rates peaked somewhat earlier
(46–55 years). CONCLUSIONS: The results suggest that schiz-
ophrenia may be more prevalent in the U.S. general population
than previously estimated in some epidemiology survey studies,
especially given the fact that claims database analyses usually
